Watson, Endo Settle Generic Lidoderm Patent Suit
The settlement agreement allows Watson to launch its 5 percent lidocaine topical patch product on Sept. 15, 2013, if the generic is approved by the U.S. Food and Drug Administration.
"We are pleased to have reached an agreement that protects Endo's intellectual property interests and eliminates the uncertainty of a court decision," Endo President and CEO...
Already a subscriber? Click here to login